Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis.

Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Abstract Text:

Shelley S Tworoger,Susan E Hankinson,

The inclusion of biomarkers measured on the continuous scale, such as endogenous sex hormones or antioxidant levels, has become common in epidemiologic studies, and introduces additional sources of error that are specific to biomarkers. This includes error associated with specimen collection, processing, and storage; laboratory error (both within and between batch); and variability in the biomarker levels over time within an individual. In this review, we discuss and recommend study design and analytic strategies to deal with these sources of measurement error. In particular we describe methods to prevent or minimize some sources of error through appropriate sample collection and storage, communication with the laboratory, proper batching of samples, and participant matching. We also discuss how to quantify error related to biomarkers, focusing on issues of quality control, pilot studies, and how to measure within-person stability over time. Further, we discuss analytic issues for dealing with laboratory and within-person variability. Finally we recommend that journals standardize the reporting of biomarker assays in scientific manuscripts.

Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Publishing Authors By Initials

SS Tworoger,SE Hankinson,

For similar diagnosis: laboratory techniques and procedures: specimen handling research abstracts see: diagnosis: laboratory techniques and procedures: specimen handling research

PUBMED ID PMID:

MEDLINE DATE:

Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Journal Published:

PUBLICATION TYPE: Review

Journal: Cancer causes & control : CCC

VOLUME: 17

Page Numbers: 889-99

Journal Abbreviation: Cancer Causes Control

ISSN: 0957-5243

DAY: 3

MONTH: Sep

YEAR: 2006

Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Information

Number of References: 48

LANGUAGE: eng

NlmUniqueID: 9100846

Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Keywords Mesh Terms:

KEYWORDS: Specimen Handling

MESH TERMS: analysis

Chemical & Substance for Abstract: Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Information

Substance Name: Biological Markers

Registry Number: 0

Grant and Affiliation Information for Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis.

AFFILIATION: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave., 3rd Floor, Boston, Massachusetts 02115, USA.

Country: Netherlands

AGENCY: United States NCI

GRANT: P01 CA87969

ACRONYM: CA

MEDLINETA: Cancer Causes Control

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis Related Publications

• A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia.
• A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer.
• A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
• A prospective study of postmenopausal hormone use and ovarian cancer risk.
• Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer.
• Association of activity and chronic disease risk factors: utility and limitations of objectively measured physical activity data.
• Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
• Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women.
• Body shape throughout life and correlations with IGFs and GH.
• Breastfeeding and risk of ovarian cancer in two prospective cohorts.
• Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer.
• Circulating colony stimulating factor-1 and breast cancer risk.
• Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
• Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer.
• Dietary patterns, the Alternate Healthy Eating Index and plasma sex hormone concentrations in postmenopausal women.
• Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
• Identification of novel dioxin-responsive genes by representational difference analysis.
• Identifying target genes of the aryl hydrocarbon receptor nuclear translocator (Arnt) using DNA microarray analysis.
• Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
• Menopausal and reproductive factors and risk of age-related macular degeneration.
• Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - exercise and premenopausal hormones.
• Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
• Plasma adiponectin concentrations and risk of incident breast cancer.
• Plasma androgen concentrations and risk of incident ovarian cancer.
• Prolactin and breast cancer risk.
• Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels.
• Reproducibility of proteomic profiles over 3 years in postmenopausal women not taking postmenopausal hormones.
• The role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon receptor action.
• Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis.
• Why does ARNT2 behave differently from ARNT?